3. SMART Medical Review: CA 19-9 and pancreatic ductal adenocarcinoma (PDAC).

David Whitcomb,Talia DeFrancesco Oranburg,Rhea Vallente,Randall E Brand
DOI: https://doi.org/10.69734/psc3br75
2024-07-10
Abstract:Carbohydrate antigen 19-9 (CA 19-9) is the sole FDA-approved serum biomarker for early detection, progression, and treatment response of pancreatic ductal adenocarcinoma (PDAC, pancreatic cancer). It is more specific than other serum biomarkers for PDAC. Understanding the clinical relevance of genetic variants and other conditions on CA 19-9 expression is thus critical for proper interpretation. This review covers PDAC risk assessment, screening, early diagnosis and treatment monitoring with a focus on CA 19-9 and genetic factors that influence serum levels with or without PDAC.
What problem does this paper attempt to address?